...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

Correct but on the flip side, the RPSs would theoretically be factored into a sale price for RVX or any part thereof reducing that sale price. The buyer has to pay those royalties out of their profit or negotiate a price to buy back the RPSs.

True, but given that I sold all my RVX shares and put a sizeable portion of the proceeds into ZHCLF shares, I'm unable to fully appreciate this flip-side problem.

Share
New Message
Please login to post a reply